10x Genomics Gains as Investors Extend Post-Earnings Rally on Atera Demand

10x Genomics (TXG) is up 13.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be driven mainly by continued optimism after the company’s August 6 second-quarter update, which included a higher full-year revenue outlook and strong commentary around early demand for its Atera platform. No clear fresh company-specific catalyst was easy to confirm today, so part of the jump could also reflect momentum buying and short-covering in a stock that still has notable short interest.

Details:

Second-quarter revenue was $151.0 million, or $149.4 million excluding a patent-litigation settlement item, and the company said that underlying revenue increased 3% from a year earlier.

Management raised full-year 2026 revenue guidance to $610 million to $630 million, up from the prior range of $600 million to $625 million.

The company said customer response to Atera was extraordinary, with booked orders already greatly exceeding the roughly 40 systems it expects to ship in 2026.

10x Genomics also pointed to strategic moves that may be supporting sentiment, including the Proteintech Genomics acquisition and new cancer-care research collaborations.

Sources:

10x Genomics, Nasdaq, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TXG Insider Trading Activity

$TXG insiders have traded $TXG stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.

Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:

SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 12 sales selling 104,677 shares for an estimated $2,700,043.
JOHN R STUELPNAGEL has made 0 purchases and 2 sales selling 20,000 shares for an estimated $1,155,055.
ADAM TAICH (Chief Financial Officer) has made 0 purchases and 2 sales selling 24,066 shares for an estimated $535,610.
SARAH A. TEICHMANN has made 0 purchases and 2 sales selling 7,551 shares for an estimated $432,278.
BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 19,421 shares for an estimated $428,778.
SHEHNAAZ SULIMAN has made 0 purchases and 2 sales selling 5,723 shares for an estimated $186,756.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$TXG Hedge Fund Activity

We have seen 199 institutional investors add shares of $TXG stock to their portfolio, and 188 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ added 4,375,792 shares (+2681.0%) to their portfolio in Q2 2026, for an estimated $167,767,865
CITADEL ADVISORS LLC added 2,035,479 shares (+273.7%) to their portfolio in Q2 2026, for an estimated $78,040,264
MILLENNIUM MANAGEMENT LLC removed 1,951,581 shares (-94.4%) from their portfolio in Q2 2026, for an estimated $74,823,615
POINT72 ASSET MANAGEMENT, L.P. added 1,852,776 shares (+inf%) to their portfolio in Q2 2026, for an estimated $71,035,431
ARK INVESTMENT MANAGEMENT LLC removed 1,714,260 shares (-14.6%) from their portfolio in Q2 2026, for an estimated $65,724,728
WELLINGTON MANAGEMENT GROUP LLP removed 1,448,765 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $30,757,280
CASDIN CAPITAL, LLC removed 1,225,000 shares (-53.8%) from their portfolio in Q2 2026, for an estimated $46,966,500

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TXG Government Contracts

We have seen $5,306,343 of award payments to $TXG over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PROSTHETIST, PROSTHETIST TECHNICIAN, AND PROSTHETIST ASSISTANT IN THE DEPARTMENT OF SURGICAL SERVICES AND R...: $371,793
GENE EXPRESSION REAGENTS: $334,142
BIOLOGICAL REAGENT MATERIAL - CHROMIUM NEXT GEM SINGLE CELL MULTIOME AND GEM-X SINGLE CELL 5 KITS AND RELAT...: $249,991
REAGENTS FOR ONGOING NGS PROJECTS (AMBIS 2270566): $249,963
IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - GEM-X UNIVERSAL GENE EXPRESSION AND CHROMIUM GEM-X SINGLE CEL...: $249,785

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$TXG Analyst Ratings

Wall Street analysts have issued reports on $TXG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 03/31/2026

To track analyst ratings and price targets for $TXG, check out Quiver Quantitative's $TXG forecast page.

$TXG Price Targets

Multiple analysts have issued price targets for $TXG recently. We have seen 9 analysts offer price targets for $TXG in the last 6 months, with a median target of $37.0.

Here are some recent targets:

Tejas Savant from Morgan Stanley set a target price of $37.0 on 07/09/2026
Patrick Donnelly from Citigroup set a target price of $45.0 on 07/08/2026
Eric Winmill from Scotiabank set a target price of $100.0 on 07/08/2026
David Westenberg from Piper Sandler set a target price of $42.0 on 07/01/2026
Luke Sergott from Barclays set a target price of $40.0 on 06/24/2026
Casey Woodring from JP Morgan set a target price of $20.0 on 05/12/2026
Kyle Mikson from Canaccord Genuity set a target price of $32.0 on 04/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.